Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
about
Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.Evaluation of universal versus genotype-guided efavirenz dose reduction in pregnant women using population pharmacokinetic modelling.Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.
P2860
Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@en
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@nl
type
label
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@en
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@nl
prefLabel
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@en
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@nl
P2093
P2860
P1476
Pharmacogenetics of efavirenz ...... oms appears to differ by race.
@en
P2093
Danielle M Richardson
David W Haas
Husamettin Erdem
Lana Olson
Megan Turner
Michael Leonard
Paul Leger
Paxton Baker
Sanika Chirwa
P2860
P304
P356
10.1097/FPC.0000000000000238
P577
2016-08-09T00:00:00Z